Diagnostic substances, in-vitro, manufacturing · New Jersey
Roche Molecular Solutions (Main)
Branchburg, NJ · ~1,038 workers · 7 years of OSHA Injury Tracking Application data.
- A
- Excellent Safety Record
- 1.6
- Avg TCR
- 3.3
- Industry avg
- 0
- Fatalities
The verdict
Roche Molecular Solutions (Main) runs at 49% of its industry's injury rate - far safer than the typical Diagnostic substances, in-vitro, manufacturing workplace, earning a grade A.
Roche Molecular Solutions (Main): 1.6 TCR = 49% of Diagnostic substances, in-vitro, manufacturing BLS 3.3 · 7y Form 300A (see methodology below)
Roche Molecular Solutions (Main) safety composite
Roche Molecular Solutions (Main) scores strongest on fatalities (safer than 50% of same-industry peers) and weakest on dart rate (safer than 27%), blended into one 0-100 breakdown against same-industry peers. A missing measure drops out and redistributes its weight rather than deflating the score. This is a per-dimension breakdown, distinct from the single letter grade above it (which weights TCR alone against the BLS industry benchmark).
38/100
Percentile-weighted across 3 of 3 measures
- Total Case Rate (TCR)
- D 1.62 per 100 workers
Safer than 41% of industry peers
- DART rate
- F 1.63 per 100 workers
Safer than 27% of industry peers
- Fatalities
- D 0
Safer than 50% of industry peers
Benchmarked live against every credibly-rated employer in the same NAICS industry code in the current OSHA extract (a segment must have at least 8 rated peers to benchmark). Not a legal or compliance determination; PlainSafetyScore's own weighting (TCR 40%, DART 35%, fatalities 25%).
TCR Δ
−0.9
2018→2024
Roche Molecular Solutions (Main) injury rate improved
Roche Molecular Solutions (Main)'s TCR fell 0.9 from 2.9 in 2018 to 2.0 in 2024. Peak filing year was 2018 at 2.9 TCR. In 2024, DART was 1.01× this establishment's average TCR (severity share of cases).
2018=2.9 · 2019=1.9 · 2020=0.8 · 2021=1.9 · 2022=1.2 · 2023=0.6 · 2024=2.0
OSHA ITA Form 300A scorecard
Establishment book 325413 · Branchburg, NJ AT/BELOW-IND · LARGE
Grade A · TCR 1.6 · 49% of ind
- DART 1.6 DART
- RANK #6/11
- PHOTO LGC Clinical Diagnos…
- BOOK 7y book
- INJ 92 inj
- SIZE ~1,038 FTE
Nearest TCR peer: LGC Clinical Diagnostics, Inc. MD (0.0 TCR gap)
Read with this employer → · Industry book → · New Jersey employers → · Look up another →
Roche Molecular Solutions (Main) in the TCR neighbourhood
Average Total Case Rate among this establishment and nearest same-industry peers
- This site
Roche Molecular Solutions (Main)
1.6 TCR
- LGC Clinical D
LGC Clinical Diagnostics, Inc. MD
1.6 TCR
- Sekisui Diagno
Sekisui Diagnostics
1.6 TCR
- Phenomenex
Phenomenex
1.6 TCR
- Bio-Rad Labora
Bio-Rad Laboratories - Redmond
1.6 TCR
What this shows Roche Molecular Solutions (Main) averages 1.6 TCR (49% of the Diagnostic substances, in-vitro, manufacturing BLS benchmark).
Roche Molecular Solutions (Main) TCR series: 2018=2.9 · 2019=1.9 · 2020=0.8 · 2021=1.9 · 2022=1.2 · 2023=0.6 · 2024=2 · BLS 3.3
Where Roche Molecular Solutions (Main) falls in its industry
201 Diagnostic substances, in-vitr establishmentsSafer than 41% of graded establishments in this industry, whose median TCR is 1.4.
Narrower to New Jersey alone (the establishments it most directly competes with for workers and contracts): ranked #6 safest of 11 Diagnostic substances, in-vitr employers in New Jersey.
Roche Molecular Solutions (Main) has more employees than the Diagnostic substances, in-vitro, manufac median and a higher injury rate than the industry's median TCR of 1.4. Workforce size and injury rate do not always move together within the same industry -- some of its smaller peers run higher rates than its larger ones, and vice versa.
Year-by-Year Safety Data
| Year | TCR | DART | Injuries | Illnesses | Fatalities |
|---|---|---|---|---|---|
| 2024 | 2.0 | 1.6 | 13 | 4 | 0 |
| 2023 | 0.6 | 0.6 | 5 | 0 | 0 |
| 2022 | 1.2 | 1.0 | 15 | 0 | 0 |
| 2021 | 1.9 | 1.5 | 21 | 0 | 0 |
| 2020 | 0.8 | 0.5 | 6 | 1 | 0 |
| 2019 | 1.9 | 0.9 | 14 | 0 | 0 |
| 2018 | 2.9 | 2.2 | 18 | 0 | 0 |
OSHA ITA peer cross-reference
Establishment peer ledger
325413 · NJ · Branchburg
201 Diagnostic substances, in-vitro, manufacturing employers nationwide with a credible TCR · 11,201 rated employers in New Jersey with headcount on file · 47 employers in Branchburg, NJ · 4 cross-state NAT-TCR peers · 4 cross-state NAT-SIZE peers. Closest matches by relationship code are listed below.
| Rel | Establishment | Metric |
|---|---|---|
| NAICS-TCR | LGC Clinical Diagnostics, Inc. MD | 1.6 TCR |
| NAICS-TCR | Sekisui Diagnostics | 1.6 TCR |
| NAICS-TCR | Phenomenex | 1.6 TCR |
| NAICS-TCR | Bio-Rad Laboratories - Redmond | 1.6 TCR |
| STATE-SIZE | NJPRS - UPS INNOVATION CENTER | 1,040 FTE |
| STATE-SIZE | Southern Ocean Medical Center | 1,036 FTE |
| STATE-SIZE | Maher Berth 64 | 1,041 FTE |
| STATE-SIZE | Global Technology Center, Colgate - Palmolive | 1,042 FTE |
| CITY-NEAR | Ferreira Construction Co. Inc. | 833 FTE |
| CITY-NEAR | Roche Molecular Systems Branchburg Site | 742 FTE |
| CITY-NEAR | Lilly Branchburg | 595 FTE |
| CITY-NEAR | 1 Millennium Way | 479 FTE |
| NAT-TCR | HOC Pleasant Grove | 1.6 TCR |
| NAT-TCR | DADCO, Inc. | 1.6 TCR |
| NAT-TCR | City of Atlanta | 1.6 TCR |
| NAT-TCR | Phoenix | 1.6 TCR |
| NAT-SIZE | Hillsboro Medical Center - Hospital | 1,038 FTE |
| NAT-SIZE | City of Phoenix F70 Public Wks | 1,038 FTE |
| NAT-SIZE | Raytheon Portsmouth_RI | 1,038 FTE |
| NAT-SIZE | OakBend Medical Center | 1,038 FTE |
Rel codes: NAICS-TCR · STATE-SIZE · CITY-NEAR · NAT-TCR/NAT-SIZE cross-state. Read with this employer →
Read our methodology - how this data is sourced, computed, and verified.